Jump to main content
Jump to site search

Issue 1, 2013
Previous Article Next Article

Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature

Author affiliations

Abstract

We systematically investigated how the therapeutic efficacy of a traceless, vascular targeting antibody–drug conjugate (ADC) is affected by the length of a spacer introduced between the antibody's globular fold and the site of drug attachment. Homogeneous ADCs were prepared from the direct conjugation of engineered C-terminal cysteines with a potent thiol containing drug which was separated from the antibody surface by unstructured spacers of increasing length. We found that a smaller spacer length is reflected in enhanced stability and therapeutic efficacy of the conjugates in a syngeneic model of murine cancer.

Graphical abstract: Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature

Back to tab navigation

Supplementary files

Publication details

The article was received on 28 Jul 2012, accepted on 05 Oct 2012 and first published on 08 Oct 2012


Article type: Edge Article
DOI: 10.1039/C2SC21107F
Citation: Chem. Sci., 2013,4, 297-302
  •   Request permissions

    Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature

    M. Steiner, I. Hartmann, E. Perrino, G. Casi, S. Brighton, I. Jelesarov, G. J. L. Bernardes and D. Neri, Chem. Sci., 2013, 4, 297
    DOI: 10.1039/C2SC21107F

Search articles by author

Spotlight

Advertisements